TroFuse-011
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- NCT06841354 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on TroFuse-011 (sacituzumab tirumotecan, pembrolizumab and 5 more in Triple Negative Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-011 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Paclitaxel; Nab-paclitaxel; Gemcitabine; Carboplatin
- Arms
- Arm A: Sacituzumab Tirumotecan · Experimental
- Arm B: Sacituzumab Tirumotecan + Pembrolizumab · Experimental
- Arm C: Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC)
- Overall Survival (OS) (sac-TMT versus TPC)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Mar 16, 2025
- Primary completion
- May 18, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06841354 · updated Oct 13, 2026
Publications
linked from the registry- Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future Oncol. 2026 Aug;22(18):2121-2129. doi: 10.1080/14796694.2026.2701483. Epub 2026 Jul 31. PubMed 42535874